source
- City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt diseaseCity Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
- Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategyIncyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…